Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KarXT for Relapse Prevention in Psychosis Associated With Alzheimer's Disease
NCT05511363Phase 3Recruiting
- Sponsor
- Karuna Therapeutics
- Start
- Aug 2022
- Primary completion
- Oct 2026
- Modality
- Small Molecules
- Countries
- 13
01
Overview
A Phase 3 trial of xanomeline in Alzheimer's disease psychosis (ADP), sponsored by Karuna Therapeutics. Started Aug 2022; status: recruiting.
02
Drugs
xanomeline
03
Conditions
Alzheimer's disease psychosis (ADP)
Beyond the preview
Go deeper on NCT05511363.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05511363.